Dependence on specific suppliers for raw materials and products
First written in FY2016. 5 of 7 entries say "Mitigated", first in FY2020. Latest entry: FY2026.
The whole theme swung hardest in 2021: 26 of 59 companies on the "Worse" side.
35 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The company has already obtained letters of consent from 25 major business partners and will continue working to obtain additional letters of consent.」
The company reconfirms that it has obtained letters of consent from 25 major business partners regarding the Sustainability Procurement Policy and Supplier Code of Conduct and will continue its efforts. - FY2025MitigatedAnnual report
「In fiscal 2024, the company obtained letters of consent from 25 major business partners. It will continue working to obtain additional letters of consent.」
Regarding the adoption of the Sustainability Procurement Policy and Supplier Code of Conduct among raw-material and product suppliers, the company obtained letters of consent from 25 major business partners in fiscal 2024. - FY2024MitigatedAnnual report
「For risk identification, in addition to questionnaire surveys based on the Nippon Shinyaku Sustainability Procurement Policy, the Group conducts surveys focused on supply stability covering suppliers of all active pharmaceutical ingredients and drug products, and works to understand the actual status of suppliers' initiatives for stable supply and BCPs (business continuity plans).」
The disclosure explicitly describes adding supply-stability and BCP surveys covering all active pharmaceutical ingredient and drug-product suppliers to address raw-material supply dependence risk, with risk-based mitigation measures then implemented. - FY2023MitigatedAnnual report
「For risks related to raw-material supplies, the Group is working to reduce risk and establish systems for a stable supply of pharmaceuticals by securing multiple suppliers and strengthening relationships with affiliated companies.」
The company reiterates its measures, including securing multiple suppliers, in response to dependence on specific business partners for raw-material supplies. - FY2021MitigatedAnnual report
「For risks related to raw-material supplies, the Group is working to reduce risk and establish systems for a stable supply of pharmaceuticals by securing multiple suppliers and strengthening relationships with affiliated companies.」
The company reiterates its measures, including securing multiple suppliers, in response to dependence on specific business partners for raw-material supplies. - FY2020MitigatedAnnual report
「For risks related to raw-material supplies, the Group is working to reduce risk and establish systems for a stable supply of pharmaceuticals by securing multiple suppliers and strengthening relationships with affiliated companies.」
In response to dependence on specific business partners for raw-material supplies, the company is securing multiple suppliers and strengthening relationships with affiliated companies. - FY2016First statedAnnual report
「Some products and important raw materials are supplied by specific business partners, so if those supplies are interrupted, the Group's operating results could be affected.」
The company identifies the risk of supply interruptions for products and important raw materials from specific business partners.